Name: SS-31
Brand: MOL Changes
SKU: 198887

SS-31 (elamipretide) bụ peptide pere mpe nke nwere anọ amino asịd; kpọmkwem ezubere iche mitochondria.

Ntinye nke oma nke akpụkpọ anụ cell bụ otu n'ime njirimara ya, na a kpọmkwem lekwasịrị anya nke n'ime mitochondrial akpụkpọ anụ.

Omenala antioxidants anaghị achịkọta nke ọma n'ime ebe a na-akpachi anya mitochondrial matrix, ngafe nfe ụdị oxygen reactive (ROS) dị ka nnukwu mgbochi.

Ụdị pụrụ iche nke SS-31 na-enye ohere maka ma neutralization nke free radicals, na iche iche electrostatic mmekọrịta/hydrophobic mmekọrịta; kpọmkwem anchoring na mitochondria n'onwe ya bụ ihe pụta kpọmkwem nke a.

Ọgwụ Mitochondrial n'ozuzu na-ahụ SS-31 dị ka otu n'ime ọgwụ ndị a na-enweta na nso nso a..

Na-agafe naanị mmetụta cytoprotective, A na-ahụkwa omume nkwughachi dị ike.

Ịkwụsị usoro ọjọọ nke nrụgide oxidative bụ ihe na-ekewa SS-31..

Na-emeziwanye myocardial ike metabolism, obere infarct nha, ọrụ obi n'ozuzu ya, na ruo n'ókè ụfọdụ, ọrụ neurodegenerative, niile dị nso.

Nkwekọrịta mmega ahụ na ike akwara na-agbakwunyere, ma dị mkpa, njedebe na SS-31 nwere ike imetụta.

Usoro

D-Arg-Dmt-Lys-Phe-NH2; Dmt=2',6'-dimethylTyr

Nọmba CAS

736992-21-5

Usoro ihe omimi

C32H49N9O5

Ibu molekụla

639.8 g/mol

Nnyocha nke SS-31

1.Ngwa Clinical na ike ọgwụgwọ

Nnwale ụlọ ọgwụ n'oge egosila mmetụta cytoprotective dị ịrịba ama – isi mitochondrial myopathies, Ọrịa Barth, obi mgbawa, nnukwu mmerụ ahụ akụrụ na akọrọ anya syndrome niile na-anọchite anya mpaghara na-ekwe nkwa nke ngwa ọgwụgwọ.

2.Mmetụta Antioxidant

A na-ekesa antioxidants ọdịnala mana dịka ekwuru n'elu enweghị ntinye a kapịrị ọnụ.

Njirimara physicochemical nke SS-31 na-enyere aka nchịkọta nhọrọ niile dị mkpa.

Nke onye inyeaka eletrọn (dimethyltyrosine) na-akpakọrịta ozugbo na neutralizes free radicals eme n'ime eletrọn njem yinye.

Nkwụsị ọkwa isi mmalite nke nrụgide oxidative bụ ebumnuche bụ isi; nchebe nke DNA mitochondrial, na-adịgide adịgide (kacha mma) mmezi nke microenvironment, na n'ezie, mmepụta ume ogologo ndụ, bụ njedebe nke ihe niile dị n'elu.

Mbelata ma ọ bụ kwụsịlata usoro ịka nká na ọtụtụ ọrịa ndị a na-apụghị ịgwọta na mbụ, bụ njedebe ikpeazụ nke usoro nyocha a.

3.Imelite ọkwa ike sistemu nke ọrịa kansa na chemotherapy mebiri

Na skeletal muscle nke ndị ọrịa cancer, mitochondrial dysfunction bụ isi ihe na-akpata ibelata Njikọ ATP; Atrophy muscle a na-apụghị ịgbagha agbagha na nrụrụ na-esote na-esote nsonaazụ ozugbo.

SS-31 na-ebelata nke ọma cachexia, na-egbochi mbelata mpaghara eriri akwara glycolytic, na-egbochi mfu mitochondrial na ụdị dị iche iche nke adịghị mma autophagy/mitosis.

Nyocha nke skeletal muscle, imeju, na metabolites plasma na-egosi mgbanwe dị ukwuu na ma ume na protein metabolism n'ime onye nnabata tumor.

4.Na-emeziwanye arụ ọrụ mitochondrial yana nsogbu ebe nchekwa jikọtara ya

Endotoxin-ụmụ oke a na-agwọ ọrịa na-egosipụta akụkụ niile nke arụrụ arụ mitochondrial a – nrụgide oxidative, nzaghachi mkpali, neuronal apoptosis, hippocampal dendritic ọkpụkpụ azụ mfu – mmụta na ike nchekwa dị mfe dị ka ihe si na ya pụta.

Nnwale na-egosi mmetụta nchebe SS-31 megide ihe ndị a kpọtụrụ aha na mbụ; modulation of Brain-derived neurotrophic factor, or abrineurin BDNF signaling as a key pathway.

Reversal of some synaptic signaling protein alterations and increased (physiological) structural complexity of synapses is observed.

Therapeutic potential for oxidative stress/neuroinflammation type damage is evident.

5.Inhibiting mitochondrial permeability transition pore (mPTP) opening to prevent apoptosis

SS-31 indirectly maintains inner mitochondrial membrane integrity, through both antioxidant and stable ATP synthesis effects.

Mee ihe ozugbo adenine nucleotide translocator (ANT) pushes up the threshold for mitochondrial permeability transition pore /mPTP opening.

Abnormal premature activation of this process is successfully inhibited; acute conditions (myocardial infarction, stroke as representative cases) can be at least partially treated by this line of inhibition.

6.Mgbochi nke nzaghachi mkparị

Ihe niile dị n'elu nwere njikọ.

A na-emeziwanye ọrụ mitochondrial, mmebi na-ebelata, na mmetụta niile dị n'okpuru ala nke mbufụt na-adịghị ala ala ma ọ bụ nnukwu ọ dịkarịa ala ebelatara.

Uru ọgwụgwọ zuru oke nke SS-31 dị na ngwakọta ndị a, ma isi, omume mgbochi mkpali.

COA

HPLC

MS

(1)Ballaro, R.; Lopalco, P.; Audrito, V.; Beltra, M.; Ntụtụ, F.; Angelini, R.; Ọgịrịga, P.; Ịnyịnya, A.; Bonetto, A.; Szeto, H. H.; et al. Ịtụle Mitochondria site na SS-31 na-eme ka ọnọdụ ike ahụ dum dị na ọrịa kansa.- na Cachexia kpatara chemotherapy. Ọrịa cancer (Basel) 2021, 13(4). DOI: 10.3390/Ọrịa cancer13040850 sitere na NLM PubMed-not-MEDLINE.

(2)Cai, J.; Jiang, Y.; Zhang, M.; Zhao, H.; Li, H.; Li, K.; Zhang, X.; Qiao, T. Mmetụta nchebe nke mitochondion-ezubere iche peptide SS-31 megide mmerụ ahụ nke ischemia-reperfusion.. J Physiol Biochem 2018, 74(2), 335-343. DOI: 10.1007/s13105-018-0617-1 Site na NLM Medline.

(3)Dai, D. F.; Chen, T.; Szeto, H.; Nieves-Cintron, M.; Mmanya nkịta, V.; Santana, L. F.; Rabinovitch, P. S. Mitochondrial lekwasịrị anya antioxidant Peptide na-emeziwanye cardiomyopathy hypertensive. J Am Coll Cardiol 2011, 58(1), 73-82. DOI: 10.1016/j.jacc.2010.12.044 Site na NLM Medline.

(4)Ding, X. W.; Robinson, M.; Li, R.; Aldhowayan, H.; Geetha, T.; Babu, J. R. Mitochondrial dysfunction na uru bara uru nke mitochondria-ezubere iche maka obere peptide SS-31 na ọrịa shuga mellitus na ọrịa Alzheimer.. Pharmacol Res 2021, 171, 105783. DOI: 10.1016/j.phrs.2021.105783 Site na NLM Medline.

(5)Mmanya na-atọ ụtọ, M. T.; Pippin, J. W.; Eng, D. G.; Hudkins, K. L.; Chiao, Y. A.; Campbell, M. D.; nke Marcin, D. J.; Alpers, C. E.; Szeto, H. H.; Rabinovitch, P. S.; Shankland, S. J. peptide ezubere iche nke mitochondrial, SS-31, na-emezi ihe owuwu glomerular n'ime ụmụ oke ndị agadi. Kidney Int 2017, 91(5), 1126-1145. DOI: 10.1016/j.kint.2016.10.036 Site na NLM Medline.

(6)Szeto, H.; Zhang, Y.; Nakagawa, Y.; osisi oak, C.; Akwụkwọ ndụ akwụkwọ ndụ, S.; Deng, X.; Rodeo, S.; Zhang, X. Nyocha nke SS-31 dị ka ebumnuche ọgwụgwọ nwere ike na ọgwụgwọ nke Tendinopathy.. Akwụkwọ akụkọ Orthopedic nke Ọgwụ Egwuregwu 2020, 8(7_nkwadebe6). DOI: 10.1177/2325967120s00395.

(7)Zhang, H.; Chen, Y.; Li, F.; Wu, C.; Cai, W.; Ee, H.; Ha bụ, H.; Ọ, M.; Kedu, L.; Wang, X.; et al. Elamipretide na-ebelata pyroptosis n'ọkpụkpụ azụ nke merụrụ ahụ site na igbochi cPLA2 nke lysosomal membrane permeabilization.. J Neuroinflammation 2023, 20(1), 6. DOI: 10.1186/s12974-023-02690-4 Site na NLM Medline.

(8)Zhao, W.; Xu, Z.; Cao, J.; Fu, Q.; Wu, Y.; Zhang, X.; Ogologo, Y.; Zhang, X.; Kedu, Y.; Li, Y.; Mi, W. Elamipretide (SS-31) na-eme ka arụ ọrụ mitochondrial dịkwuo mma, synapti na ebe nchekwa ihe kpatara lipopolysaccharide n'ime ụmụ oke. J Neuroinflammation 2019, 16(1), 230. DOI: 10.1186/s12974-019-1627-9 Site na NLM Medline.

Usoro:	D-Arg-Dmt-Lys-Phe-NH2; Dmt=2',6'-dimethylTyr
CAS:	736992-21-5
M.W:	639.8 g/mol

SS-31